Sirius Therapeutics

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
Factor XIRNA / oligonucleotide
Atherosclerotic Cardiovascular DiseaseVenous Thromboembolism
Phase 1/2
LPA gene / apolipoprotein(a) mRNARNA / oligonucleotide
Atherosclerotic Cardiovascular Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
SRSD107Phase 2Coronary Artery Disease (CAD), Peripheral Arterial Disease
Est. primary completion 2027-12 · NCT07318155 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 March 2026PresentationSRSD216Phase 1 SRSD216 Lp(a) data presented at ACC 2026
Sirius Therapeutics · Source ↗

Financial reports

No financial reports recorded.